Clinical Trials
3 trialsNCT05492682 2026-05-12
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Phase 1 Recruiting
NCT06946225 2026-01-08
ACTengine® IMA203 Combined With mRNA-4203
Immatics US, Inc.
Phase 1 Recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting